💧 Peritonitis Diagnosis Peritoneal Dialysis Simulator

Recognizing Peritonitis in the Peritoneal Dialysis Patient

Peritoneal dialysis (PD) uses the peritoneal membrane itself as the dialysis surface, which means the peritoneal cavity is directly exposed to the outside world through the PD catheter every time a bag exchange is performed. Peritonitis — inflammation and infection of the peritoneum — remains the most common serious complication of PD and the leading cause of technique failure and transfer to hemodialysis. Recognizing the presenting picture early is the first and most important diagnostic step.

• ~97%: Cloudy effluent sensitivity (for peritonitis when present)
• 80–95%: Abdominal pain frequency (of confirmed episodes)
• 30–50%: Fever incidence (often low-grade or absent)
• ~0.2–0.3: Peritonitis rate (modern era) (episodes / patient-year)

The classic presenting triad

Patients on PD who develop peritonitis most commonly present with a combination of:

• Cloudy or turbid dialysate effluent — the single most sensitive sign; a patient who reports "milky" or "cloudy" bags should be treated as having peritonitis until proven otherwise • Abdominal pain — typically diffuse, sometimes with rebound tenderness or guarding; pain severity does not always correlate with infection severity • Additional features: fever (often modest, sometimes absent — especially in patients on immunosuppression or with uremia blunting the febrile response), nausea, vomiting, and diarrhea or constipation

Because the peritoneal cavity is accessed multiple times daily for exchanges, the differential for a contaminated or touch-break exchange is broad — but any cloudy bag should immediately raise concern regardless of how mild the patient otherwise feels.

Cloudy effluent plus abdominal pain, together, has a very high positive predictive value for peritonitis in a PD patient and should trigger immediate collection of effluent for cell count, Gram stain, and culture — treatment should not be delayed while awaiting laboratory confirmation.

Why rapid recognition matters

Unlike many other infections, PD peritonitis has a self-inoculating anatomical route: bacteria that gain entry — via the catheter lumen (touch contamination), the exit site and tunnel (pericatheter infection), transmurally from the bowel, or hematogenously — encounter a large, richly vascularized serosal surface that can rapidly amplify a local infection into systemic illness.

Delays in recognition and treatment are associated with: • Progression to sepsis and hemodynamic instability • Peritoneal membrane damage from prolonged inflammation, leading to ultrafiltration failure over time • Higher rates of relapse, catheter loss, and permanent transfer to hemodialysis • Increased mortality, particularly in episodes caused by more virulent organisms

For this reason, international guidelines (ISPD) recommend that any PD patient reporting cloudy effluent contact their PD unit immediately, and that effluent sampling and empiric treatment begin without waiting for a full outpatient work-up.

Effluent Cell Count — The Quantitative Diagnostic Anchor

While symptoms raise suspicion, the diagnosis of PD peritonitis is formally anchored by the effluent white cell count and its differential. A properly drawn sample — from a dwell that has been in the abdomen long enough for cells to accumulate — showing an elevated white cell count dominated by neutrophils is one of the three classic diagnostic criteria (alongside cloudy effluent/symptoms and a positive culture).

• >100 /µL: WBC diagnostic threshold (with dwell ≥ 2 hours)
• >50%: Neutrophil predominance (of total effluent WBCs)
• >90%: Criteria sensitivity (2 of 3 met) (illustrative, per ISPD framework)
• Minutes: Turnaround (bedside count) (manual or automated counter)

Why cell count and differential, not just turbidity

Visual cloudiness of effluent correlates with an elevated cell count but is an imperfect surrogate — some infected dwells appear only mildly turbid, and some non-infectious causes (chemical irritation, eosinophilic peritonitis, chylous effluent, intraperitoneal blood, or recently instilled fibrin) can cloud the fluid without true bacterial infection. The effluent white cell count and differential give a quantitative, laboratory-confirmable answer.

Key principles applied when interpreting the count:

• Dwell time matters: a very short dwell (e.g., an effluent drained soon after a fresh exchange) has not had time to accumulate cells, and a falsely low count can be misleading — an adequate dwell duration (commonly at least 2 hours) is required for the count to be diagnostically meaningful • Neutrophil predominance is the key differential finding: bacterial peritonitis recruits polymorphonuclear neutrophils (PMNs) rapidly, so a differential showing more than half neutrophils strongly supports an infectious, bacterial process • A high total WBC count with lymphocyte or eosinophil predominance instead points toward alternative or overlapping diagnoses (eosinophilic peritonitis, mycobacterial or fungal processes, or a resolving/partially treated episode)

Illustrative diagnostic threshold: an effluent white cell count greater than 100 cells/µL (from a dwell of adequate duration) together with more than 50% neutrophils supports a diagnosis of peritonitis — this is one of the three classic ISPD-style criteria used alongside cloudy effluent/symptoms and microbiologic confirmation.

Practical bedside and laboratory workflow

In practice, the effluent sample is sent for:

1. Total and differential white cell count — manual hemocytometer count or automated cell counter, reported as cells/µL along with the percentage of neutrophils, lymphocytes, monocytes, and eosinophils 2. Gram stain — performed in parallel (see Stage 3) 3. Culture — performed in parallel, ideally with a technique that maximizes yield (see Stage 3)

Because the cell count can be obtained rapidly, it functions as the fastest objective evidence available to the clinician at presentation — often available well before culture results — and is used together with the clinical picture to decide whether to start empiric antibiotics immediately rather than waiting 24–72 hours for culture data.

Effluent Culture and Gram Stain — Identifying the Causative Organism

Once peritonitis is suspected on clinical and cell-count grounds, effluent is sent for Gram stain and culture. Gram stain can occasionally give a rapid preliminary clue to the organism class, while culture — read over the following one to several days — provides definitive organism identification and antibiotic susceptibility, which together guide the transition from broad empiric therapy to targeted, narrower-spectrum treatment and inform prognosis.

• ~10–40%: Gram stain positivity (often negative even in true infection)
• <15%: Culture-negative rate target (with optimized technique, per ISPD goals)
• ~60–70%: Gram-positive organisms (coagulase-negative staph, S. aureus, streptococci)
• ~2–10%: Fungal / higher-risk organisms (associated with worse outcomes)

Maximizing culture yield

A meaningful fraction of clinically diagnosed peritonitis episodes can return a negative culture if suboptimal technique is used, which undermines organism-directed therapy. Steps used to maximize yield include:

• Sending an adequate volume of effluent — small aliquots dramatically reduce sensitivity because bacterial density in effluent can be low • Concentrating the sample — centrifuging effluent and culturing the resuspended sediment/pellet, or inoculating blood culture bottles directly at the bedside, substantially increases yield compared with simply sending raw fluid to the lab • Collecting the sample before antibiotics are given whenever feasible, since even a single empiric dose can suppress growth • Extending incubation and using both aerobic and anaerobic media to capture fastidious or slow-growing organisms

A well-run PD program tracks its own culture-negative rate as a quality metric — a persistently high culture-negative rate suggests a technique problem in specimen collection or processing that should be corrected.

What the organism tells the clinician

The identified organism shapes both treatment and prognosis:

• Coagulase-negative staphylococci — often related to touch contamination during exchanges; generally respond well to appropriate antibiotics with a favorable prognosis • Staphylococcus aureus — more virulent, often linked to catheter exit-site or tunnel infection; higher relapse and catheter-loss risk, particularly with methicillin resistance • Gram-negative organisms (e.g., Pseudomonas, E. coli, Klebsiella) — may signal a transmural/bowel source (Pseudomonas in particular is associated with difficult-to-eradicate biofilm on the catheter) and often needs combination therapy • Polymicrobial (multiple organisms) growth — raises concern for an intra-abdominal surgical source (perforation, ischemic bowel, cholecystitis) and warrants prompt surgical evaluation • Fungal organisms (Candida species) — carry the highest risk of treatment failure and are a near-universal indication for catheter removal (see Stage 5)

Gram stain, when positive, gives an early hint (gram-positive cocci vs. gram-negative rods vs. yeast) that can help refine empiric coverage even before final culture and sensitivities return.

Because certain organisms — especially fungi and some resistant gram-negative rods — carry substantially higher rates of treatment failure and relapse, organism identification is not just about picking the right antibiotic; it materially changes the probability that the catheter itself will need to be removed.

Empiric Intraperitoneal Antibiotic Initiation — Treat First, Refine Later

Once the diagnostic picture supports peritonitis — cloudy effluent and abdominal pain, an elevated neutrophil-predominant effluent white cell count — broad empiric intraperitoneal antibiotic therapy is started immediately, without waiting for culture results. Empiric regimens are deliberately designed to cover both gram-positive and gram-negative organisms simultaneously, since the causative organism is unknown at the moment treatment must begin.

• Gram+ AND Gram-: Coverage strategy (dual empiric coverage)
• Intraperitoneal: Typical route (delivered directly into a dwell)
• As soon as possible: Time to first dose (target) (after sample collection)
• Culture + sensitivity: Regimen narrowed by (usually within 48–72h)

Why treatment cannot wait for culture

Culture results typically take one to several days to finalize, but untreated peritonitis can progress quickly to sepsis and can inflict cumulative damage on the peritoneal membrane the longer it is allowed to smolder. For this reason, once the clinical and cell-count picture is consistent with peritonitis, empiric intraperitoneal antibiotics are started at the point of care — often the same visit the effluent sample is collected — rather than waiting for microbiology to confirm the organism.

Empiric regimens are built to simultaneously cover:

• Gram-positive organisms (the most common category overall) — typically covered with an agent such as a first-generation cephalosporin or vancomycin, chosen partly based on local resistance patterns (e.g., local MRSA prevalence) • Gram-negative organisms — typically covered with an agent such as a third-generation cephalosporin or an aminoglycoside

The intraperitoneal route is preferred when feasible because it delivers high local antibiotic concentrations directly to the site of infection — the peritoneal cavity — often achieving levels far higher than would be reached systemically for a given dose.

The guiding principle is "cover broadly first, narrow later": empiric therapy is intentionally redundant in its coverage because missing the causative organism in the first 24–72 hours carries a real cost in delayed clearance, membrane injury, and risk of progression to a refractory or relapsing course.

From broad coverage to targeted therapy

Once Gram stain and, more definitively, culture and sensitivity results become available (Stage 3), the empiric regimen is reassessed and narrowed:

• If a single organism with known susceptibilities is identified, therapy is switched to the narrowest effective agent — reducing resistance pressure and side-effect burden while maintaining efficacy • If cultures remain negative despite a convincing clinical picture, empiric broad-spectrum coverage is typically continued for a full treatment course, guided by clinical response • If the organism identified is one associated with a higher failure rate (e.g., Pseudomonas, or especially fungi), the treatment plan is reassessed early — this may mean adding a second agent, or moving toward the catheter-removal discussion covered in Stage 5

Throughout treatment, the patient is monitored clinically (resolution of pain, fever) and by serial effluent clarity/cell counts, forming the basis for the response assessment in the final stage.

Monitoring Treatment Response — and When the Catheter Has to Come Out

After empiric (and then targeted) antibiotics are started, clinical status and effluent clarity are tracked over the treatment course to confirm the infection is resolving. Most episodes respond well and clear fully. But persistent cloudy effluent, relapsing infection with the same organism, or an organism with a low probability of medical cure — most notably fungi — can require removal of the peritoneal catheter as the only reliable way to fully eradicate the infection.

• 48–96h: Expected clinical improvement (illustrative response window)
• Majority: Typical uncomplicated resolution (of episodes with prompt therapy)
• Near-universal: Fungal peritonitis catheter removal (recommendation once identified)
• Minority: Overall catheter removal rate (of all peritonitis episodes)

What a good response looks like

A favorable treatment course is tracked through several converging signals:

• Symptomatic improvement — resolution of abdominal pain and tenderness, resolution of fever if present • Effluent clarity — bags progressively clearing from cloudy/turbid back toward normal clear-to-pale-yellow appearance • Falling effluent white cell count and neutrophil percentage on repeat sampling • Clinical stability — no evolution toward hemodynamic instability or signs of an intra-abdominal surgical process

If these markers are trending favorably, the identified (or empiric) antibiotic course is continued for the planned duration, and the catheter is preserved — successful medical cure without catheter loss is the goal and the outcome in the majority of properly treated episodes.

When catheter removal becomes necessary

In a subset of episodes, medical therapy alone cannot fully clear the infection, because bacteria (and especially fungi) can form a biofilm on the catheter surface that antibiotics penetrate poorly. Indications that typically prompt catheter removal include:

• Refractory peritonitis — failure to respond clinically (persistently cloudy effluent, ongoing symptoms) after an adequate trial of appropriate antibiotics, generally assessed within about 5 days • Relapsing peritonitis — recurrence of infection with the same organism shortly after apparently successful treatment, suggesting a biofilm reservoir on the catheter that was never fully eradicated • Fungal peritonitis — Candida and other fungal organisms are very difficult to eradicate from an indwelling catheter with antifungal therapy alone; catheter removal is recommended essentially as soon as a fungal organism is identified, rather than waiting to see if therapy fails • Refractory exit-site/tunnel infection occurring together with peritonitis from the same organism • Signs of an intra-abdominal surgical source (e.g., fecal peritonitis, abscess) requiring surgical management

After catheter removal, the patient is typically transitioned to hemodialysis for a period of antibiotic treatment and recovery, with the option of a new PD catheter placement later once the infection has fully cleared.

The catheter-removal decision is a branch point rather than a failure of the diagnostic process: it reflects a specific, recognized biology — biofilm-protected organisms, especially fungi — for which removing the foreign material is what actually cures the infection, not a stronger antibiotic.